| Subject: | FDA Issues Public Health Alert About New USP Standards for Heparin Products That Will Result in Decreased Potency |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 1 Oct 2009 - 02:00 pm |
| The U.S. Food and Drug Administration (FDA) is alerting health care professionals to a change in heparin manufacturing that is expected to decrease the potency of the common blood-clotting drug. To ensure the quality of heparin and to guard against potential contamination, the United States Pharmacopeia (USP), a nonprofit standards-setting organization, adopted new manufacturing controls for heparin. These changes include a modification of the reference standard for the drug's unit... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
